Bilirubin Blood Test Market size is projected to reach US$ 2.72 Billion by 2034 from US$ 1.5 Billion in 2025. The market is anticipated to register a CAGR of 6.86% from 2026 to 2034. Rising demand for liver function assessment and neonatal jaundice screening is driving growth. Advances in automated analyzers and point-of-care testing are expected to support adoption.
Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00018027
Key Players Analysis:
Koninklijke Philips N.V.
Beckman Coulter, Inc.
Thermo Fisher Scientific Inc.
Randox Laboratories Ltd.
F. Hoffmann-La Roche AG
Dragerwerk AG & Co. KGaA
Ginevri
Advanced Instruments
Reichert, Inc.
The bilirubin blood test market is demonstrating steady clinical growth, stimulated by routine diagnostic screening utilizing total serum bilirubin (TSB) tests, direct/conjugated bilirubin tests, and indirect/unconjugated bilirubin tests across automated laboratory instruments and specialized reagent consumables. Crucial for diagnosing neonatal hyperbilirubinemia, adult jaundice, liver cirrhosis, hepatitis, and hemolytic anemias, bilirubin testing is a core parameter in routine clinical chemistry. Global diagnostic and clinical laboratory giants including F. Hoffmann-La Roche AG, Beckman Coulter, Inc. (Danaher), Thermo Fisher Scientific Inc., and Randox Laboratories Ltd. are engineering high-throughput photometric and diazo-method chemistry analyzers. In conjunction, recognized neonatal and point-of-care medical innovators such as Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Advanced Instruments, Reichert, Inc., and Ginevri are delivering non-invasive transcutaneous bilirubinometers and clinical micro-osmometers.
Market Segmentation:
- By Test Type (Total Serum Bilirubin Test, Direct/Conjugated Bilirubin Test, Indirect/Unconjugated Bilirubin Test)
- By Product Type (Consumables, Instruments)
Bilirubin Blood Test Market Dynamics, Regional Analysis, and Future Outlook –
Market Challenges –
Challenges include the need for analytical accuracy, sample handling consistency, equipment calibration, and quality control. Differences between laboratory and point-of-care methods, testing costs, limited diagnostic infrastructure, and the need to interpret results alongside other clinical findings can affect use and market adoption.
Market Opportunities –
Opportunities include automated clinical chemistry platforms, point-of-care testing, neonatal bilirubin assessment, and improved laboratory information system integration. Expansion of diagnostic laboratories, newborn care services, and access to routine blood testing in emerging markets may support adoption of faster and more accessible testing solutions.
Regional Analysis –
North America is supported by established clinical laboratories, hospital testing, and neonatal care. Europe benefits from developed diagnostic infrastructure and laboratory quality systems. Asia Pacific offers opportunities through expanding diagnostic networks, large newborn populations, and increasing healthcare access. Latin America and the Middle East and Africa may see growth as laboratory capacity and routine diagnostic services improve.
Market Drivers –
The bilirubin blood test market is driven by the need to diagnose and monitor liver disorders, bile duct conditions, hemolytic diseases, and neonatal jaundice. Routine clinical chemistry testing, newborn screening and assessment, and monitoring of patients with liver-related conditions support demand for laboratory analyzers and bilirubin assay reagents.
Recent Industry Developments –
Industry developments include ongoing improvements in automated bilirubin assays, analyzer throughput, quality-control processes, and integration of test results into electronic laboratory systems. Diagnostic providers are also emphasizing standardized testing workflows and timely assessment of bilirubin levels in neonatal and adult care.
Future Analysis and Forecast –
The market is expected to remain supported by routine liver function assessment, neonatal care, and monitoring of relevant medical conditions. Future development may focus on automation, faster turnaround times, improved assay reliability, and integration with laboratory information systems. Growth will depend on testing volumes, access to diagnostic facilities, reagent affordability, and advances in clinical chemistry platforms.
Get Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00018027
Recent industry developments in the bilirubin blood test market highlight automated transcutaneous bilirubinometers, point-of-care microfluidic assay cassettes, and high-sensitivity total serum bilirubin (TSB) chemiluminescent immunoassay reagents. Diagnostic testing developers are refining non-invasive optical screening devices that measure skin reflectance to evaluate neonatal jaundice rapidly without painful heel-stick blood sampling. Current market trends emphasize high demand for portable, battery-operated bilirubinometers in maternity wards and home health visits. The future outlook remains exceptionally favorable, propelled by universal clinical guidelines mandating pre-discharge jaundice screening in newborns.
About Us
The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.
Contact Us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
